West Coast Sarcoma Conference 2024: Session 5 – Special Problems in GIST
OR
Chair
Dr. Christine Simmons
Speakers
Dr. Jinesa Moodley
Dr. Xiaolan Feng
Dr. Alannah Smrke
Dr. Trevor Hamilton
Studies/trials discussed:
- NCCN task force report: Management of patients with Gastrointestinal Stromal Tumor (GIST) Update of the NCCN clinical practice guidelines
- Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediateor High-Risk Primary Gastrointestinal Stromal Tumor -The PERSIST-5 Clinical Trial
- Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China
- Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis
- Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy
- Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -analysis of prognostic factors (EORTC-STBSG collaborative study)
- Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels
